University of Southampton

southampton.ac.uk

Total trials

119

Active

23

Phase 3

5

Total enrollment

2,257,446

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 12 of 12 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Flucloxacillin Only Product in Oral Dose Form1
Mitomycin c1
Rituximab2
Ifosfamide2
Carboplatin2
Pembrolizumab1
Etoposide1
Trastuzumab deruxtecan1
BMS-9865041
PD-1 vaccine IMU-2011
Bordetella pertussis B19172
Azithromycin Pill1

Next readouts

  • 2026-03-31
  • 2026-05
  • 2026-05-30
  • 2026-12-01
  • 2027-03-31
  • 2027-07
  • 2028-09

Top conditions

  • Stroke6
  • Asthma5
  • Parkinson Disease4
  • Colorectal Cancer3
  • Chronic Obstructive Pulmonary Disease3
  • Meningitis, Bacterial3
  • Malnutrition3
  • Chronic Pain3

Frequently asked questions about University of Southampton

How many clinical trials does University of Southampton have on ClinicalTrials.gov?
University of Southampton is listed as the lead sponsor on 119 clinical trials in ClinicalTrials.gov, 23 of which are currently active (recruiting, enrolling, or ongoing).
How many of University of Southampton's trials are in Phase 3?
5 of University of Southampton's trials are in Phase 3, spread across 12 active drug programs.
What therapeutic areas does University of Southampton focus on?
University of Southampton's most-studied conditions on ClinicalTrials.gov are Stroke, Asthma, Parkinson Disease, Colorectal Cancer, Chronic Obstructive Pulmonary Disease.
When are University of Southampton's next clinical trial readouts?
University of Southampton has 7 upcoming primary-completion readouts tracked here; the soonest is “Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer”, expected around 2026-03-31.